BeiGene
BGNE
#914
Rank
ยฃ17.28 B
Marketcap
ยฃ153.49
Share price
-0.42%
Change (1 day)
2.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -ยฃ0.71 Billion

According to BeiGene 's latest financial reports the company's current earnings are ยฃ3.09 Billion. In 2023 the company made an earning of -ยฃ0.96 Billion, an increase over its 2022 earnings that were of -ยฃ1.43 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.71 Billion-26.67%
2023 -ยฃ0.96 Billion-32.52%
2022 -ยฃ1.43 Billion24.39%
2021 -ยฃ1.15 Billion-13.21%
2020 -ยฃ1.32 Billion72.69%
2019 -ยฃ0.77 Billion36.01%
2018 -ยฃ0.57 Billion616.83%
2017 -ยฃ78.13 Million-15.24%
2016 -ยฃ92.18 Million107.91%
2015 -ยฃ44.34 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ14.41 Million-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.2 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA